According to Novartis Group, the results of the 12th batch of centralized procurement of nationally organized drugs were announced on July 31. Novartis cubaclvalsartan sodium tablets were selected in this centralized procurement. The selection in this collection involved heart failure indications of this product. Meanwhile, according to public information from the State Intellectual Property Office, one of Novartis's core patents for sacubatl valsartan sodium tablets has been compensated for a drug patent period of 1,826 days based on a marketing license for essential hypertension indications. The patent protection period after compensation expires on November 8, 2031.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.